From Yahoo Finance: 2025-05-23 01:49:00

Genmab A/S (NASDAQ:GMAB) to present pivotal new research at the 2025 ASCO Annual Meeting, including results from a Phase 1/2 trial of Rina-S for endometrial cancer. Also sharing long-term data on epcoritamab for DLBCL. Investor webcast on Rina-S data scheduled for June 2 during ASCO.

Genmab A/S (NASDAQ:GMAB) Chief Development Officer highlights commitment to advancing antibody science, particularly for women with endometrial cancer. Collaboration with ABBV ongoing for epcoritamab trials in B-cell malignancies. Investor webcast on Rina-S data set for June 2 during ASCO.

Despite GMAB’s potential, some believe AI stocks offer higher returns with limited downside risk. Looking for an AI stock with 100x upside potential? Check out a report on the cheapest AI stock for more promising investment opportunities. No disclosure provided.

For more information on cancer stocks and investment opportunities, check out the “10 Best Cancer Stocks to Invest in for Long-Term Gains” and “10 Most Oversold Stocks to Buy According to Billionaires” articles. No disclosure provided.

Read more: Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025